[Platelet activation and platelet aggregation in the arteriosclerotic endothelium: pathophysiological aspects and new therapeutic concepts].
Pongratz
G
G
Medizinische Klinik II und Poliklinik, Universität Erlangen-Nürnberg.
Pohle
K
K
Stingl
D
D
Bachmann
K
K
D000925:Anticoagulants / Q000494:pharmacology; D001161:Arteriosclerosis / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000473:pathology* / Q000503:physiopathology; D006801:Humans; D015539:Platelet Activation / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors; D017482:Receptors, Thromboxane / Q000037:antagonists & inhibitors; D013917:Thrombin / Q000037:antagonists & inhibitors; D013927:Thrombosis / Q000517:prevention & control / Q000628:therapy*; D013988:Ticlopidine / Q000494:pharmacology
D000925:Anticoagulants; D016861:Cyclooxygenase Inhibitors; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D013917:Thrombin; D013988:Ticlopidine
Thrombozytenaktivierung und Thrombozytenaggregation am arteriosklerotisch veränderten Endothel. Pathophysiologische Aspekte und neue therapeutische Konzepte.